Page 77 - Flipbook January Board
P. 77

Robert Packer Hospital

 Clinical Quality Committee Meeting


 DATE:  Tuesday, December 11, 2018

 TIME:  Noon
 Present: Joseph Ronsivalle, DO (Chair), Douglas Trostle, MD, Willow Bronson-Golay, Kelly Coldiron, Barb Pennypacker, Jill Stenson, Nicole
 Teeter, Vania Brown-Small, Barb Gordon, Michael Gum, Barbara Hayes, Renee Jankowski, Kim Joedicke, Andrew Klee, Deb Luchaco, Melissa,
 Susan Sinay, Kim Worden, Sergio Zullich, Janet Cunningham, Kristen Nash, DO.

 Meeting Started: 12:02 PM                                                 Meeting Adjourned: 1:02 PM
 TOPIC   DISCUSSION/CONCLUSION                                RECOMMENDATIONS/
                                                               ACTION/FOLLOW UP
                                                              /RESPONSIBLE PARTY

 I.    Old Business   Minutes from December 11, 2018 were reviewed. Dr. Ronsivalle motioned to accept   Minutes Approved
 minutes as presented, seconded by Sergio Zullich and Janet Cunningham. There was no
 dissent.
 II.  Pharmacy &   Kim Joedicke provided report from Pharmacy and Therapeutics Committee.   Motion to approve formulary
 Therapeutics – Copy of   •  Reported Adverse Drug Reactions (ADRs) and Medication Errors for October   changes and policy revisions
 presentation attached to   2018 included 31 ADRs with 2 determined to be preventable and 21 medication   made by Dr. Ronsivalle,
 official minutes   errors.                                seconded by Jill Stenson and
 •  Infusion Center formulary changes for approval:        Dr. Trostle, there was no
 o  Add Infliximab-Abda (Renflexis) as second biosimilar to Remicade (first   dissent. Motion carried.
 biosimilar is Inflectra). Inflectra is the most cost effective and should be

 first choice for NEW starts unless insurance dictates otherwise.
 o  Conversion of IVIG from Gammunex-C to Privigen. Privigen is currently
 the most cost effective IVIG product. All new starts should use Privigen.
 Current patients will transition to Privigen at the approval of their provider
 with a new order. Potential annual cost savings of $130,000 systemwide.
 •  Policy changes for approval:
 o  Controlled Medications RPH-A-744-2202 revised, nursing will no longer
 inventory controlled substances in Automated Dispensing Machines.
 o  Medication Storage and Security RPH-A-744-2200 revised to include
 dispensing process for first doses on cartless units and the stocking
 process for IV fluids by Supply and Distribution personnel.
 o  Medication Dispensing and Distribution RPH-A-744-4100 revised to
 include bedside medication boxes as a medication storage location.
 o  Omnicell Anesthesia System RPH-A-744-2208 revised due to the
 transition from Aesynt Anesthesia Carts to Omnicell Anesthesia Carts.
 •  P&T Committee to review Andexanet Alfa (Andexxa) which reverses bleeding
 related to the use of Rivaroxaban (Xarelto) and Apixaban (Eliquis) ONLY.


                                                                                             1
   72   73   74   75   76   77   78   79   80   81   82